Literature DB >> 20975515

Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease.

Carolyn W Zhu1, Elayne E Livote, Kristin Kahle-Wrobleski, Nikolaos Scarmeas, Marilyn Albert, Jason Brandt, Deborah Blacker, Mary Sano, Yaakov Stern.   

Abstract

This study explores the longitudinal relationship between patient characteristics and use of 4 drug classes (antihypertensives, antidepressants, antipsychotics, and hormones) that showed significant changes in use rates over time in patients with Alzheimer disease. Patient/caregiver-reported prescription medication usage was categorized by drug class for 201 patients from the Predictors Study. Patient characteristics included use of cholinesterase inhibitors and/or memantine, function, cognition, living situation, baseline age, and sex. Assessment interval, year of study entry, and site were controlled for. Before adjusting for covariates, useage increased for antihypertensives (47.8% to 62.2%), antipsychotics (3.5% to 27.0%), and antidepressants (32.3% to 40.5%); use of hormones decreased (19.4% to 5.4%). After controlling for patient characteristics, effects of time on the use of antidepressants were no longer significant. Antihypertensive use was associated with poorer functioning, concurrent use of memantine, and older age. Antipsychotic use was associated with poorer functioning and poorer cognition. Antidepressant use was associated with younger age, poorer functioning, and concurrent use of cholinesterase inhibitors and memantine. Hormone use was associated with being female and younger age. Findings suggest accurate modeling of the Alzheimer disease treatment paradigm for certain subgroups of patients should include antihypertensives and antipsychotics in addition to cholinesterase inhibitors and memantine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20975515      PMCID: PMC3075380          DOI: 10.1097/WAD.0b013e3181fcba68

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  25 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

3.  Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial.

Authors:  V W Henderson; A Paganini-Hill; B L Miller; R J Elble; P F Reyes; D Shoupe; C A McCleary; R A Klein; A M Hake; M R Farlow
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

Review 4.  Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.

Authors:  Kaycee M Sink; Karen F Holden; Kristine Yaffe
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

5.  The course of psychopathologic features in mild to moderate Alzheimer disease.

Authors:  D P Devanand; D M Jacobs; M X Tang; C Del Castillo-Castaneda; M Sano; K Marder; K Bell; F W Bylsma; J Brandt; M Albert; Y Stern
Journal:  Arch Gen Psychiatry       Date:  1997-03

6.  Multicenter study of predictors of disease course in Alzheimer disease (the "predictors study"). I. Study design, cohort description, and intersite comparisons.

Authors:  Y Stern; M Folstein; M Albert; M Richards; L Miller; F Bylsma; G Lafleche; K Marder; K Bell; M Sano
Journal:  Alzheimer Dis Assoc Disord       Date:  1993       Impact factor: 2.703

7.  Multicenter study of predictors of disease course in Alzheimer disease (the "predictors study"). II. Neurological, psychiatric, and demographic influences on baseline measures of disease severity.

Authors:  M Richards; M Folstein; M Albert; L Miller; F Bylsma; G Lafleche; K Marder; K Bell; M Sano; D Devanand
Journal:  Alzheimer Dis Assoc Disord       Date:  1993       Impact factor: 2.703

8.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Stephen R Rapp; Mark A Espeland; Sally A Shumaker; Victor W Henderson; Robert L Brunner; JoAnn E Manson; Margery L S Gass; Marcia L Stefanick; Dorothy S Lane; Jennifer Hays; Karen C Johnson; Laura H Coker; Maggie Dailey; Deborah Bowen
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Authors:  Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

10.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.

Authors:  Mark A Espeland; Stephen R Rapp; Sally A Shumaker; Robert Brunner; JoAnn E Manson; Barbara B Sherwin; Judith Hsia; Karen L Margolis; Patricia E Hogan; Robert Wallace; Maggie Dailey; Ruth Freeman; Jennifer Hays
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

View more
  3 in total

1.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

2.  Serum brain-derived neurotrophic factor levels in different neurological diseases.

Authors:  Mariacarla Ventriglia; Roberta Zanardini; Cristina Bonomini; Orazio Zanetti; Daniele Volpe; Patrizio Pasqualetti; Massimo Gennarelli; Luisella Bocchio-Chiavetto
Journal:  Biomed Res Int       Date:  2013-08-19       Impact factor: 3.411

Review 3.  The treatment of hypertension in people with dementia: a systematic review of observational studies.

Authors:  Tomas J Welsh; John R Gladman; Adam L Gordon
Journal:  BMC Geriatr       Date:  2014-02-12       Impact factor: 3.921

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.